JGC
MRNS

J. Goldman & Co’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

J. Goldman & Co’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,632
Closed -$53K – 460
2017
Q4 		$53K Sell
1,632
-11,868
-88% -$320K ﹤0.01% 311
2017
Q3 		$317K Sell
13,500
-83,822
-86% -$940K 0.02% 291
2017
Q2 		$533K Buy
+97,322
New +$526K 0.03% 242
2016
Q3 		– Sell
-136,823
Closed -$695K – 434
2016
Q2 		$695K Buy
+136,823
New +$2.52M 0.04% 273

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

J. Goldman & Co's MRNS Position: Q1 2018 in Review

J. Goldman & Co sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2018, closing a stake of 1,632 shares — an estimated $53K sold.

J. Goldman & Co first reported a position in MRNS in Q2 2016 and held it in 4 quarters. The position peaked at $695K in Q2 2016. 60 funds tracked by Wall St. Rank hold MRNS as of Q1 2018.

  • J. Goldman & Co reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • J. Goldman & Co sold 1,632 Marinus Pharmaceuticals, Inc shares in Q1 2018, an estimated $53K.
  • J. Goldman & Co first reported a position in Marinus Pharmaceuticals, Inc in Q2 2016 and held it in 4 quarters.
  • J. Goldman & Co's Marinus Pharmaceuticals, Inc position peaked at $695K in Q2 2016.
  • 60 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2018.

Based on J. Goldman & Co's 13F filing for Q1 2018, filed 15 May 2018.